All In Biotech

Drug Trial Radar · NCT01762787

Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers

A Randomised, Single Blind, Placebo-Controlled, Cross-over, Phase 1 Methodology Study to Validate the Cantharidin Blister Model in Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Aug 17, 2010

Primary completion

Jan 14, 2011

Study completion Jan 14, 2011

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Other
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to refine the cantharidin-induced blister assay in healthy volunteers as a model of inflammatory disease. The study is an experimental trial in healthy volunteers in two parts; Part 1 to optimise the model and Part 2 to validate using two anti-inflammatory treatments with different modes of action.

Conditions

  • Inflammation

Interventions

  • Cantharidin solutionDrug

    5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3

  • AspirinDrug

    300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only

  • PrednisoloneDrug

    30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only

  • Placebo to aspirinDrug

    0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only

  • Placebo to prednisoloneDrug

    0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blister volume of fluidTime frame: 48 hours
  2. Cell population in blister fluidTime frame: 48 hours
  3. Inflammatory mediators in blister fluidTime frame: 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.